Table 3.

Susceptibilities of Candida strains to fluconazole, P-113, and Nal-P-113 in modified LYM medium

Candida sp.SourceStrainMIC (μg/ml)
FluconazoleControl50 mM NaCl100 mM NaCl150 mM NaCl
P-113NalP-113NalP-113NalP-113Nal
C. kruseiATCC 6258YLO6326.256.256.256.251006.2510012.5
C. parapsilosisATCC 22019YLO786.256.255012.5>10012.5>10025
C. glabrataATCC 9003YLO81612.56.25>10025>10025>10025
C. albicansATCC 90028YLO1216.256.252512.510012.5>10012.5
C. tropicalisATCC 13803YLO86>643.16.253.16.2512.56.2512.56.25
C. albicansHIV patientYH05000126.256.252512.510012.5>10012.5
C. albicansHIV patientYH05000516.256.255025>10025>10025
C. tropicalisHIV patientYH050007>643.16.253.16.25256.252512.5
C. tropicalisHIV patientYH050013>643.16.253.16.25506.255012.5
C. albicansHIV patientYH050072>646.256.252525>10025>10025
C. kruseiHIV patientYH050075646.256.252512.5>10012.5>10012.5
C. dubliniensisHIV patientYH0500920.56.256.2512.512.5>10012.5>10012.5
C. glabrataHIV patientYH050105166.256.255012.510025>10050
C. tropicalisHIV patientYH050114>643.16.253.16.251006.2510012.5